Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

P0300000

Paracetamol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Acetaminophen, 4′-Hydroxyacetanilide, 4-Acetamidophenol, N-(4-Hydroxyphenyl)acetamide, N-Acetyl-4-aminophenol, APAP, Paracetamol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
CH3CONHC6H4OH
CAS Number:
103-90-2
Molecular Weight:
151.16
Beilstein/REAXYS Number:
2208089
EC Number:
203-157-5
MDL number:
MFCD00002328
UNSPSC Code:
41116107
PubChem Substance ID:
329820028
NACRES:
NA.24

grade

pharmaceutical primary standard

description

API family: acetaminophen

API family

paracetamol, acetaminophen

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

168-172 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(=O)Nc1ccc(O)cc1

InChI

1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)

Inchi Key

RZVAJINKPMORJF-UHFFFAOYSA-N

Gene Information

human ... FAAH(2166) , PTGS1(5742) , PTGS2(5743) , TRPV1(7442)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Paracetamol EP reference standard, intended for use only as specifically prescribed in the European Pharmacopoeia.
Analgesic.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Product No.
Description
Pricing

PHR1005

Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1148

4-Aminophenol (Acetaminophen Related Compound K) (Paracetamol Impurity K), Pharmaceutical Secondary Standard; Certified Reference Material

PHR1149

Acetaminophen Related Compound J, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1150

Acetaminophen Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

1003009

Acetaminophen, United States Pharmacopeia (USP) Reference Standard

1021204

4-Aminophenol, United States Pharmacopeia (USP) Reference Standard

PHR1225

3-Aminophenol, Pharmaceutical Secondary Standard; Certified Reference Material

1003010

Acetaminophen Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1531

Acetaminophen Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1530

Acetaminophen Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1612

Acetaminophen Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

1003027

Acetaminophen Related Compound B, United States Pharmacopeia (USP) Reference Standard

1003042

Acetaminophen Related Compound D, United States Pharmacopeia (USP) Reference Standard

1003100

Acetaminophen Related Compound J, United States Pharmacopeia (USP) Reference Standard

1003031

Acetaminophen Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1642

Acetaminophen Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

1003064

Acetaminophen Related Compound F, United States Pharmacopeia (USP) Reference Standard

1026004

m-Aminophenol, United States Pharmacopeia (USP) Reference Standard

Y0001781

Paracetamol for equipment qualification, European Pharmacopoeia (EP) Reference Standard

PHR1745

4-Aminophenol hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP371

Paracetamol, British Pharmacopoeia (BP) Reference Standard

Y0001945

Paracetamol impurity J, European Pharmacopoeia (EP) Reference Standard

Y0001955

Paracetamol impurity K, European Pharmacopoeia (EP) Reference Standard

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

364.3 °F - Pensky-Martens closed cup

flash_point_c

184.6 °C - Pensky-Martens closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Garry G Graham et al.
Drug safety, 28(3), 227-240 (2005-03-01)
The excellent tolerability of therapeutic doses of paracetamol (acetaminophen) is a major factor in the very wide use of the drug. The major problem in the use of paracetamol is its hepatotoxicity after an overdose. Hepatotoxicity has also been reported
Garry G Graham et al.
Inflammopharmacology, 21(3), 201-232 (2013-05-31)
Paracetamol is used worldwide for its analgesic and antipyretic actions. It has a spectrum of action similar to that of NSAIDs and resembles particularly the COX-2 selective inhibitors. Paracetamol is, on average, a weaker analgesic than NSAIDs or COX-2 selective
Mitchell R McGill et al.
Pharmaceutical research, 30(9), 2174-2187 (2013-03-07)
Acetaminophen (APAP) is one of the most widely used drugs. Though safe at therapeutic doses, overdose causes mitochondrial dysfunction and centrilobular necrosis in the liver. The first studies of APAP metabolism and activation were published more than 40 years ago.
S M de Morais et al.
Gastroenterology, 102(2), 577-586 (1992-02-01)
Gilbert's syndrome occurs in 5%-7% of the human population and is caused by an inherited deficiency in the glucuronidation of endogenous bilirubin, resulting in its accumulation and jaundice. The authors of the present study have previously shown that rats with
Karel Allegaert et al.
Archives of disease in childhood, 98(6), 462-466 (2013-04-23)
There remains a need for alternative medical treatments for patent ductus arteriosus (PDA) closure in extreme preterm neonates because of therapeutic failure and adverse effects associated with non-selective cyclo-oxygenase inhibitors. Reports of an association between paracetamol exposure and PDA closure
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service